Introducing: The Next Evolution in Diagnostic Excellence
The Xpert® GI Panel from Cepheid Now Available
Clinically Relevant. Purposefully Designed.
The new Xpert GI Panel delivers accurate, clinically relevant detection of key GI pathogens in a single, streamlined test – helping clinicians act fast while supporting laboratory efficiency and diagnostic stewardship.
Why Xpert GI Panel?
11 Targets. ~74 Minutes to Results. <1 Minute Hands-On Time. One Cartridge = The Smart Answer
How the Xpert GI Panel Supports Your Stewardship Goals:
Whether you’re a clinician, head of lab, microbiology leader, or antimicrobial stewardship champion, the Xpert GI Panel provides the confidence and speed needed to make informed decisions – without adding complexity.
Comprehensive Detection
Results in ~74 minutes support early treatment decisions, infection control, and informed patient management.
Results That Impact Care
Identify 11 clinically relevant GI pathogens, including bacteria, viruses, and parasites, in one test – reducing the need for multiple orders and follow-up testing.
Minimal Hands-On Time
With <1 minute of hands-on time, labs can reduce manual steps, improve consistency, and optimize staff time.
Support Stewardship Goals
Targeted multiplex PCR reduces unnecessary treatments and supports diagnostic stewardship.1
Proven GeneXpert® Technology
Built on trusted GeneXpert systems, already in use across U.S. hospitals and laboratories.
Clinical and Operational Impact

Ready to optimize your GI testing workflow?
Complete the form below to be contacted by a Cepheid Representative:
Which Viruses, Bacteria and Parasites Does the Xpert GI Panel Detect?

Salmonella

Shigella/EIEC

Campylobacter

STEC Stx1 & Stx2 (Shiga toxin-producing E. coli)

Yersinia enterocolitica

Vibrio cholerae

Vibrio parahaemolyticus

Giardia

Cryptosporidium

Norovirus GI/GII
Take the Next Step
See how the Xpert GI Panel can support faster diagnosis and better care for your institution.
CE-IVD. In Vitro Diagnostic Medical Device. May not be available in all countries.
1. Chase, J., Mohandas, A., Devani, D., Manning, B., Schulz, L., & Goss, T. (2025, October). Comparison of target detection rates of multiplex gastrointestinal PCR panels: A systematic literature review & meta-analysis
2. Michael A. Lewinski, Kevin Alby, N. Esther Babady, Susan M. Butler-Wu, Jennifer Dien Bard, Alexander L. Greninger, Kimberly Hanson, Samia N. Naccache, Duane Newton, Robyn L. Temple-Smolkin, Frederick Nolte, Exploring the Utility of Multiplex Infectious Disease Panel Testing for Diagnosis of Infection in Different Body Sites: A Joint Report of the Association for Molecular Pathology, American Society for Microbiology, Infectious Diseases Society of America, and Pan American Society for Clinical Virology, The Journal of Molecular Diagnostics, Volume 25, Issue 12, 2023, Pages 857-875, ISSN 1525-1578, https://doi.org/10.1016/j.jmoldx.2023.08.005.
3. Jenkins DR, Auckland C, Chadwick C, Dodgson AR, Enoch DA, Goldenberg SD, Hussain A, Martin J, Spooner E, Whalley T. A practical approach to screening for carbapenemase-producing Enterobacterales- views of a group of multidisciplinary experts from English hospitals. BMC Infect Dis. 2024 Apr 26;24(1):444. doi: 10.1186/s12879-024-09307-y. PMID: 38671365; PMCID: PMC11046869.
About Cepheid
Cepheid is dedicated to improving healthcare by pioneering molecular diagnostics that combine speed, accuracy, and flexibility. The company's GeneXpert® systems and Xpert® tests automate highly complex and time-consuming manual procedures, providing A Better Way for institutions of any size to perform world-class PCR testing. Cepheid's broad test portfolio spans respiratory infections, blood virology, women's and sexual health, TB and emerging infectious diseases, healthcare-associated infectious diseases, oncology and human genetics. The company's solutions deliver actionable results where they are needed most from central laboratories and hospitals to near patient settings.
For more information, visit www.cepheid.com

©2026 Cepheid. All Rights Reserved.